CCC
SBIO icon

Crescent Capital Consulting’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Crescent Capital Consulting’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$253K Hold
6,000
– – 0.04% 158
2021
Q3 		$274K Hold
6,000
– – 0.05% 154
2021
Q2 		$293K Hold
6,000
– – 0.05% 143
2021
Q1 		$302K Hold
6,000
– – 0.07% 140
2020
Q4 		$307K Buy
+6,000
New +$285K 0.08% 121

Other funds holding SBIO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MC
Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
NAM
NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Crescent Capital Consulting's SBIO Position: Q4 2021 in Review

Crescent Capital Consulting held its ALPS Medical Breakthroughs ETF (SBIO) position steady in Q4 2021 at 6,000 shares worth $253K. The position accounts for 0.04% of the portfolio, ranked #158.

Crescent Capital Consulting first reported a position in SBIO in Q4 2020 and has held it in 5 quarters since. The position peaked at $307K in Q4 2020. 66 funds tracked by Wall St. Rank hold SBIO as of Q4 2021.

  • Crescent Capital Consulting held 6,000 shares of ALPS Medical Breakthroughs ETF worth $253K as of Q4 2021.
  • Crescent Capital Consulting left its ALPS Medical Breakthroughs ETF share count unchanged in Q4 2021.
  • ALPS Medical Breakthroughs ETF made up 0.04% of Crescent Capital Consulting's portfolio in Q4 2021, its #158 holding.
  • Crescent Capital Consulting first reported a position in ALPS Medical Breakthroughs ETF in Q4 2020 and has held it in 5 quarters since.
  • Crescent Capital Consulting's ALPS Medical Breakthroughs ETF position peaked at $307K in Q4 2020.
  • 66 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.